{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:15:44Z","timestamp":1772165744809,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>As we all know, patients with epithelial ovarian carcinoma have poor prognosis and high recurrence rate. It is critical and challenging to screen out the patients with high risk of recurrence. At present, there are some models predicting the overall survival of epithelial ovarian carcinoma, however, there is no widely accepted tool or applicable model predicting the recurrence risk of epithelial ovarian carcinoma patients. The objective of this study was to establish and verify a nomogram to predict the recurrence risk of EOC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed the clinicopathological and prognostic data of 193 patients with EOC who achieved clinical complete remission after cytoreductive surgery and chemotherapy between January 2003 and December 2013 in Peking University First Hospital. The nomogram was established with the risk factors selected by LASSO regression. The medical data of 187 EOC patients with 5-year standard follow-up in Peking University Third Hospital and Beijing Obstetrics and Gynecology Hospital were used for external validation of the nomogram. AUC curve and Hosmer-Lemeshow test were used to evaluate the discrimination and calibration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The nomogram for 3-year recurrence risk was established with FIGO stage, histological grade, histological type, lymph node metastasis status and serum CA125 level at diagnosis. The total score can be obtained by adding the grading values of these factors together. The C statistics was 0.828 [95% CI, 0.764\u20130.884] and the Chi-square value is 3.6 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.731\u2009&gt;\u20090.05) with the training group. When the threshold value was set at 198, the sensitivity, specificity, positive predictive value, negative predictive value and concordance index were 88.8, 67.0, 71.8, 86.3% and 0.558 respectively. In the external validation, the C statistics was 0.803 [95%CI, 0.738\u20130.867] and the Chi-square value is 11.04 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.135\u2009&gt;\u20090.05). With the threshold value of 198, the sensitivity, specificity, positive predictive value, negative predictive value and concordance index of the nomogram were 75.7, 77.0, 83.2, 67.9%, and 0.52 respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We established and validated a nomogram to predict 3-year recurrence risk of patients with EOC who achieved clinical complete remission after cytoreductive surgery and chemotherapy. This nomogram with good discrimination and calibration might be useful for screening out the patients with high risk of recurrence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-07402-2","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T11:04:28Z","timestamp":1601377468000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Establishment and verification of the nomogram that predicts the 3-year recurrence risk of epithelial ovarian carcinoma"],"prefix":"10.1186","volume":"20","author":[{"given":"Jun","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobing","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3818-9545","authenticated-orcid":false,"given":"Lirong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"key":"7402_CR1","doi-asserted-by":"publisher","first-page":"e555","DOI":"10.1016\/S2214-109X(18)30127-X","volume":"6","author":"H Zeng","year":"2018","unstructured":"Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6:e555\u201367.","journal-title":"Lancet Glob Health"},{"key":"7402_CR2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34\u201343.","journal-title":"N Engl J Med"},{"key":"7402_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/jnci\/95.2.105","volume":"95","author":"JB Trimbos","year":"2003","unstructured":"Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, et al. International collaborative ovarian neoplasm trial 1 and adjuvant ChemoTherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003;95:105\u201312.","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 6","key":"7402_CR4","doi-asserted-by":"publisher","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","volume":"24","author":"JA Ledermann","year":"2013","unstructured":"Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi24\u201332.","journal-title":"Ann Oncol"},{"key":"7402_CR5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ygyno.2009.10.074","volume":"116","author":"JK Chan","year":"2010","unstructured":"Chan JK, Tian C, Teoh D, Monk BJ, Herzog T, Kapp DS, et al. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a gynecological oncology group study. Gynecol Oncol. 2010;116:307\u201311.","journal-title":"Gynecol Oncol"},{"key":"7402_CR6","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/IGC.0b013e3181c104c0","volume":"20","author":"M Polcher","year":"2010","unstructured":"Polcher M, Friedrichs N, Rudlowski C, Fimmer R, Keyver- Paik MD, K\u00fcbler K, et al. Changes in Ki-67 labeling indices during neoadjuvant chemotherapy for advanced ovarian cancer are associated with survival. Int J Gynecol Cancer. 2010;20:555\u201360.","journal-title":"Int J Gynecol Cancer"},{"key":"7402_CR7","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1158\/1538-7445.AM2012-589","volume":"32","author":"H Kim","year":"2012","unstructured":"Kim H, Kim K, No JH, Jeon YT, Jeon HW, Kim YB. Prognostic value of biomarkers related to drug resistance in patients with advanced epithelial ovarian cancer. Anticancer Res. 2012;32:589\u201394.","journal-title":"Anticancer Res"},{"key":"7402_CR8","doi-asserted-by":"publisher","first-page":"107877","DOI":"10.18632\/oncotarget.14112","volume":"8","author":"M Chen","year":"2017","unstructured":"Chen M, Yao S, Cao Q, Xia M, Liu J, He M. The prognostic value of Ki67 in ovarian high-grade serous carcinoma: an 11-year cohort study of Chinese patients. Oncotarget. 2017;8:107877\u201385.","journal-title":"Oncotarget"},{"key":"7402_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s12094-008-0213-x","volume":"10","author":"A Garcia-Velasco","year":"2008","unstructured":"Garcia-Velasco A, Mendiola C, Sanchez-Munoz A, Ballest\u00edn C, Colomer R, Cort\u00e9s-Funes H. Prognostic value of hormonal receptors, p53, ki67 and HER2\/neu expression in epithelial ovarian carcinoma. Clin Transl Oncol. 2008;10:367\u201371.","journal-title":"Clin Transl Oncol"},{"key":"7402_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/ijgo.12769","volume":"14","author":"A Ditto","year":"2019","unstructured":"Ditto A, Leone Roberti Maggiore U, Bogani G, Martinelli F, Chiappa V, Evangelista MT, et al. Predictive factors of recurrence in patients with early-stage epithelial ovarian cancer. Int J Gynaecol Obstet. 2019;14:28\u201333.","journal-title":"Int J Gynaecol Obstet"},{"key":"7402_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ejogrb.2014.01.014","volume":"175","author":"H Kajiyama","year":"2014","unstructured":"Kajiyama H, Mizuno M, Shibata K, Yamamoto E, Kawai M, Nagasaka T, et al. Recurrence-predicting prognostic factors for patients with early-stage epithelial ovarian cancer undergoing fertility-sparing surgery: a multi-institutional study. Eur J Obstet Gynecol Reprod Biol. 2014;175:97\u2013102.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"7402_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1177\/030089160909500212","volume":"95","author":"H Karagol","year":"2009","unstructured":"Karagol H, Saip P, Eralp Y, Topuz S, Berkman S, Ilhan R, et al. Factors related to recurrence after pathological complete response to postoperative chemotherapy in patients with epithelial ovarian cancer. Tumori. 2009;95:207\u201311.","journal-title":"Tumori"},{"key":"7402_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2217\/bmm.15.110","volume":"10","author":"C Chang","year":"2016","unstructured":"Chang C, Chiang AJ, Chen WA, et al. A joint model based on longitudinal CA125 in ovarian cancer to predict recurrence. Biomark Med. 2016;10:53\u201361.","journal-title":"Biomark Med"},{"key":"7402_CR14","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/IGC.0000000000000361","volume":"25","author":"I Rizzuto","year":"2015","unstructured":"Rizzuto I, Stavraka C, Chatterjee J, Borley J, Hopkins TG, Gabra H, et al. Risk of ovarian Cancer relapse score: a prognostic algorithm to predict relapse following treatment for advanced ovarian cancer. Int J Gynecol Cancer. 2015;25:416\u201322.","journal-title":"Int J Gynecol Cancer"},{"key":"7402_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00404-008-0877-z","volume":"280","author":"SM Lenhard","year":"2009","unstructured":"Lenhard SM, Bufe A, Kumper C, Stieber P, Mayr D, Hertlein L, et al. Relapse and survival in early-stage ovarian cancer. Arch Gynecol Obstet. 2009;280:71\u20137.","journal-title":"Arch Gynecol Obstet"},{"key":"7402_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13048-016-0266-3","volume":"9","author":"ZJ Yang","year":"2016","unstructured":"Yang ZJ, Zhao BB, Li L. The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer. J Ovarian Res. 2016;9:57.","journal-title":"J Ovarian Res"},{"key":"7402_CR17","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1470-2045(13)70253-5","volume":"14","author":"W Sieh","year":"2013","unstructured":"Sieh W, Kobel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, et al. Hormone-receptor expression and ovarian cancer survival: an ovarian tumor tissue analysis consortium study. Lancet Oncol. 2013;14:853\u201362.","journal-title":"Lancet Oncol"},{"key":"7402_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/IGC.0b013e3182788466","volume":"23","author":"D Zhao","year":"2013","unstructured":"Zhao D, Zhang F, Zhang W, He J, Zhao Y, Sun J, et al. Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer. 2013;23:25\u201333.","journal-title":"Int J Gynecol Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07402-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07402-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07402-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,20]],"date-time":"2022-11-20T23:34:08Z","timestamp":1668987248000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07402-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7402"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07402-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-41532\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-41532\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-41532\/v3","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]},"assertion":[{"value":"12 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Ethics Committee of the First Hospital of Peking University. The number of ethical review was No. (2018) Scientific Research No. (109). Written informed consent was obtained from all individual participants included in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"938"}}